Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries

4 Feb 2023

Abstract excerpt

Baseline rilpivirine drug resistance mutations (DRMs) are a risk factor for virological failure in patients treated with long-acting cabotegravir and rilpivirine (CAB/RPV LA). We investigated rilpivirine cross-resistance in treatment-naive and experienced patients in South Africa. One in 10 treatment-naive patients and 74.5% of patients failing treatment presented with rilpivirine DRMs. Our data suggest targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment
Share to Respiratory viral infections research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36779485
DOI: 10.1097/qad.0000000000003505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countriesPMID 36779485Read ↗

Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries.Semantic proximity Read ↗

Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications.Semantic proximity Read ↗

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis.Semantic proximity Read ↗

Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.Semantic proximity Read ↗

Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.Semantic proximity Read ↗

Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons.Semantic proximity Read ↗

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trialSemantic proximity Read ↗

Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.Semantic proximity Read ↗

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patientsSemantic proximity Read ↗

Drug Resistance Mutations (DRMs) for Long-Acting Injectable Cabotegravir and Rilpivirine (CAB/RPV LAI) in the HIV-1 Subtype A6 Epidemic in PolandSemantic proximity Read ↗

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland.Semantic proximity Read ↗

Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.